Aristo Bio-Tech & Lifescience Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹80 Cr
- P/E
- 11.18
- ROE
- 17.63%
- PEG
- 0.42
- Price to sales
- 0.22
- Debt to equity
- 0.80
- 52W high / low
- ₹144 / ₹74.3
- Sales growth (5Y)
- 16.85%
- EBITDA margin
- 4.41%
- Net profit margin
- 1.97%
- Promoter holding
- 73.42%
- Sales (last year)
- ₹364 Cr
Incorporated in 2005, Aristo Bio-Tech and Lifescience Ltd manufactures and supplies pesticides and agrochemicals[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Fertilizers & Agrochemicals
on management's own guidance
- Insecticides IndiaGood growth2
- Anya Polytech &Good growth1
- Madhya Bharat Agro ProductsGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Aristo Bio-Tech & Lifescience shareholding (Sep 2026)
Promoters
73.42%
unchanged QoQ
FIIs
—
— QoQ
DIIs
—
— QoQ
Public
26.58%
unchanged QoQ
Peers
Fertilizers & Agrochemicals companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | Anya Polytech & | 20–40% | Up 2%+ | ₹209 Cr | 25.0 |
| 2 | Insecticides India | 20–40% | Up 0–2% | ₹1,591 Cr | 13.0 |
| 3 | Madhya Bharat Agro Products | 20–40% | Flat | ₹9,124 Cr | 58.9 |
| 4 | 20–40% | Flat | ₹7,714 Cr | 39.2 | |
| 5 | 10–20% | Flat | ₹53,862 Cr | 33.7 | |
| 6 | 10–20% | Flat | ₹15,672 Cr | 8.2 |
Sign up free to see every company in the sector ranking and track Aristo Bio-Tech.
Pro shows every company guiding 40%+ revenue growth →Full Fertilizers & Agrochemicals rankingFinancials of Aristo Bio-Tech
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Aristo Bio-Tech
Shareholding breakup across reporting periods.
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters + | 73.37% | 73.37% | 73.37% | 73.37% | 73.42% | 73.42% | 73.42% | 73.42% |
| Public + | 26.62% | 26.63% | 26.63% | 26.63% | 26.58% | 26.58% | 26.58% | 26.58% |
| No. of Shareholders | 660 | 652 | 742 | 625 | 512 | 468 | 453 | 442 |
Financials of Aristo Bio-Tech
Quarterly Results
Quarter-by-quarter operating performance
Financials of Aristo Bio-Tech
Profit & Loss
Annual income statement trend
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 57 | 159 | 271 | 202 | 201 | 167 | 166 | 218 | 245 | 318 | 364 |
| Sales growth | +180% | +70% | -26% | -0% | -17% | -1% | +31% | +13% | +30% | +14% | |
| Expenses + | 56 | 157 | 263 | 195 | 197 | 163 | 160 | 209 | 236 | 309 | 348 |
| Operating Profit | 1 | 3 | 7 | 7 | 5 | 4 | 5 | 9 | 8 | 9 | 16 |
| OPM % | 1.6% | 1.6% | 2.7% | 3.4% | 2.2% | 2.6% | 3.3% | 4.0% | 3.5% | 2.9% | 4.4% |
| Other Income + | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
| Profit before tax | 1 | 3 | 6 | 4 | 1 | 2 | 2 | 5 | 5 | 5 | 10 |
| Tax % | 33% | 31% | 34% | 31% | 28% | 28% | 28% | 25% | 28% | 26% | 26% |
| Net Profit + | 0 | 2 | 4 | 3 | 1 | 1 | 1 | 4 | 4 | 4 | 7 |
| EPS in Rs | 0.80 | 3.70 | 7.48 | 5.67 | 2.02 | 2.16 | 2.14 | 5.23 | 5.73 | 5.96 | 10.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 7% | 10% | 6% |
Financials of Aristo Bio-Tech
Balance Sheet
Capital structure and asset base
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 7 | 7 | 7 | 7 |
| Reserves | 2 | 4 | 7 | 6 | 7 | 8 | 10 | 23 | 27 | 31 | 37 |
| Borrowings + | 5 | 10 | 20 | 14 | 20 | 22 | 25 | 22 | 21 | 22 | 35 |
| Other Liabilities + | 20 | 72 | 60 | 65 | 56 | 46 | 37 | 47 | 73 | 81 | 76 |
| Total Liabilities | 27 | 87 | 89 | 91 | 88 | 81 | 77 | 100 | 127 | 141 | 155 |
| Fixed Assets + | 2 | 2 | 8 | 8 | 8 | 12 | 14 | 16 | 22 | 24 | 24 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 25 | 85 | 81 | 81 | 77 | 69 | 63 | 83 | 106 | 117 | 131 |
| Total Assets | 27 | 87 | 89 | 91 | 88 | 81 | 77 | 100 | 127 | 141 | 155 |
Financials of Aristo Bio-Tech
Cash Flows
Operating, investing and financing cash movement
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -4 | 1 | 8 | 1 | 2 | 7 | -3 | 8 | 10 | 9 | |
| Cash from Investing Activity + | 0 | -5 | -2 | -2 | -2 | -3 | -4 | -7 | -5 | -3 | |
| Cash from Financing Activity + | 4 | 4 | -6 | 1 | -1 | -3 | 8 | -2 | -4 | -4 | |
| Net Cash Flow | 0 | -0 | -0 | 0 | -0 | 0 | 1 | -1 | 0 | 2 | |
| Free Cash Flow | -4 | 0 | 6 | -1 | 0 | 4 | -7 | 1 | 5 | 6 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -123% | 38% | 138% | 40% | 60% | 134% | -17% | 106% | 123% | 71% |
Financials of Aristo Bio-Tech
Ratios
Working capital efficiency and return ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 121 | 65 | 77 | 88 | 72 | 73 | 75 | 86 | 65 | 55 |
| Inventory Days | 66 | 67 | 42 | 65 | 47 | 78 | 60 | 57 | 65 | 59 | 70 |
| Days Payable | 142 | 177 | 85 | 124 | 74 | 93 | 87 | 85 | 112 | 97 | 78 |
| Cash Conversion Cycle | 16 | 11 | 23 | 18 | 61 | 56 | 46 | 48 | 38 | 26 | 47 |
| Working Capital Days | 3 | 14 | 14 | 15 | 20 | 28 | 25 | 36 | 31 | 22 | 24 |
| ROCE % | 31% | 34% | 24% | 14% | 11% | 12% | 16% | 13% | 13% | 20% |
Aristo Bio-Tech & Lifescience: frequently asked questions
What is Aristo Bio-Tech & Lifescience share price today?
Aristo Bio-Tech & Lifescience last traded at ₹117.9, with a market capitalisation of ₹80 Cr and a P/E ratio of 11.2.
What is the promoter holding in Aristo Bio-Tech & Lifescience?
Promoters held 73.42% of Aristo Bio-Tech & Lifescience in Sep 2026 (unchanged versus Mar 2026).
What is Aristo Bio-Tech & Lifescience's ROE and ROCE?
Aristo Bio-Tech & Lifescience's return on equity is 17.6% and its return on capital employed is 19.6%.
Does Aristo Bio-Tech & Lifescience pay a dividend?
Yes. Aristo Bio-Tech & Lifescience's dividend yield is 0.51% at the current price. The full payout history is on the Aristo Bio-Tech & Lifescience dividends page.
Which sector does Aristo Bio-Tech & Lifescience belong to?
Aristo Bio-Tech & Lifescience is in the Fertilizers & Agrochemicals sector. Its peer comparison and sector ranking are on this page.
What did Aristo Bio-Tech & Lifescience's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Aristo Bio-Tech & Lifescience's management.
How does Arthneeti AI analyse Aristo Bio-Tech & Lifescience?
Arthneeti reads Aristo Bio-Tech & Lifescience's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Aristo Bio-Tech's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Madhya Bharat Agro Products (Q2 FY27)
Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo
- Dhansa Labs (Q2 FY27)
1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Krishana Phoschem (Q2 FY27)
Year-on-year revenue growth: Rs 70,254.28 Lakhs vs Rs 60,786.41 Lakhs (~15.6% increase) . Key results statement takeaways from Krishana Phoschem Ltd's Q2 FY27 e
- Balaji Phosphates (Q2 FY27)
Year-on-year growth for the half year (Standalone): ~31.4% increase (from Rs. Key results statement takeaways from Balaji Phosphates Ltd's Q2 FY27 results state
